Adagio Medical, Inc. (NASDAQ: ADGM) is a clinical‐stage medical device company dedicated to developing minimally invasive therapies for structural heart disease. The company’s core focus lies in designing catheter‐based solutions that address conditions such as mitral regurgitation and thromboembolism risk associated with the left atrial appendage. By leveraging novel implant geometries and low‐profile delivery systems, Adagio Medical aims to provide permanent, durable treatments that can be delivered through minimally invasive access pathways.
The company’s lead product candidates include a transseptal mitral annuloplasty system designed to reshape and stabilize the mitral valve annulus, as well as a percutaneous left atrial appendage occluder intended to reduce stroke risk in patients with atrial fibrillation. Both platforms employ nitinol‐based frames and biocompatible sealing membranes that conform to patient‐specific anatomies. These devices are fully retrievable and repositionable prior to final deployment, allowing physicians to optimize placement under real-time imaging guidance.
Headquartered in Irvine, California, Adagio Medical conducts its preclinical research and early feasibility studies at major cardiovascular centers across North America and Europe. The company’s manufacturing footprint includes an ISO-certified production facility in Southern California, while its research and development team collaborates closely with leading academic institutions and contract research organizations to advance product design and execute clinical trials. Regulatory engagement efforts are underway in both the United States and European Union, with planned submissions to seek investigational device approvals and CE marking.
Adagio Medical is led by a seasoned management team with deep expertise in medical device engineering, regulatory strategy, and interventional cardiology. The board of directors features former executives and clinical investigators from top cardiovascular device companies, ensuring strategic oversight throughout product development and commercialization. As the company progresses its clinical programs, it continues to forge partnerships with key opinion leaders and healthcare institutions to bring next-generation structural heart therapies to patients globally.
AI Generated. May Contain Errors.
Free ADGM Stock Alerts